Composition, quality control, and labeling of plasma-derived products for the treatment of von Willebrand disease

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 5, 2006, Pages 529-536

  Mazurier, Claudine ^a  

^a Laboratoire Francais du Fractionnement et des Biotechnologies   (France)

Author keywords

Collagen binding activity; Factor concentrates; Ristocetin cofactor activity; Von Willebrand disease (vWD); Von Willebrand factor (vWF)

Indexed keywords

BIOSTATE; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; CONFACT F; EMOCLOT; FANDHI; KOATE DVI; VON WILLEBRAND FACTOR; WILATE; WILFACTIN;

ARTICLE; HEMOPHILIA A; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PURIFICATION; QUALITY CONTROL; SAFETY; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VON WILLEBRAND DISEASE;

BIOLOGICAL PRODUCTS; BLOOD PROTEINS; FACTOR VIII; HUMANS; PLASMA; QUALITY ASSURANCE, HEALTH CARE; QUALITY CONTROL; SAFETY; VON WILLEBRAND DISEASE;

EID: 33746595318     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-947868     Document Type: Article

References (33)

1. Jorpes JE, Blombäck B, Blombäck M, et al. A pilot plant for the preparation of a human plasma fraction containing the human antihaemophilic factor A (factor VIII) and von Willebrand's factor. Acta Med Scand 1962;379(suppl): 7-21
2. Perkins HA. Correction of the hemostatic effects in von Willebrand's disease. Blood 1967;30:375-380
3. Blatt PM, Brinkhous KM, Culp HR, et al. Antihemophilic factor concentrate therapy in von Willebrand disease: dissociation of bleeding-time factor and ristocetin-cofactor activities. JAMA 1976;236:2770-2772
4. Green D, Potter EV. Failure of AHF concentrate to control bleeding in von Willebrand's disease. Am J Med 1976;60: 357-360
5. Mazurier C, Jorieux S, de Romeuf C, et al. In vitro evaluation of a very-high-purity solvent/detergent treated, von Willebrand factor concentrate. Vox Sang 1991;61:1-7
6. Turecek PL, Gritsch H, Pichler L, et al. In vivo characterization of recombinant von Willebrand factor in dogs with von Willebrand disease. Blood 1997;90:3555-3567
7. Thompson AR, Gill JC, Ewenstein BM, et al. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate P). Haemophilia 2004;10:42-51
8. Gill JC, Ewenstein BM, Thompson AR, et al. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003;9:688-695
9. Mannucci PM, Chediak J, Hanna W, et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002;99:450-456
10. Lillicrap D, Poon MC, Walker I, et al. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, Haemate-P/Humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002;87:224-230
11. Cohen AJ, Kessler CM, Ewenstein BM, et al. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia 2001;7:235-241
12. Srivastava A, Mathews V, Bhurani D, et al. Successful surgical hemostasis in patients with von Willebrand disease following infusion of Koate® DVI. Thromb Haemost 2002;87:541-543
13. Federici AB. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys. Blood Coagul Fibrinolysis 2005; 16:S17-S21
14. The European Agency for the Evaluation of Medicinal Products. Note for Guidance on Plasma-Derived Medicinal Products. CPMP/269/95, rev. 2. London: Human Medicines Evaluation Unit; 1997
15. Shord SS, Lindley CM. Coagulation products and their uses. Am J Health Syst Pharm 2000;57:1403-1417
16. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004;10:243-249
17. Allford SL, Harrison P, Lawrie AS, et al. Von Willebrand factor-cleaving protease activity in congenital thrombotic thrombocytopenic purpura. Br J Haematol 2000;111:1215-1222
18. Makris M, Colvin B, Gupta V, et al. Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand's disease. Thromb Haemost 2002;88:387-388
19. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002;88:378-379
20. Mazurier C, Poulle M, Samor B, et al. In vitro study of a triple-secured von Willebrand factor concentrate. Vox Sang 2004;86:100-104
21. Favaloro EJ, Bukuya M, Martinelli T, et al. A comparative multi-laboratory assessment of three factor VIII/von Willebrand factor concentrates. Thromb Haemost 2002;87:466-476
22. Menache D, Aronson DL. New treatments of von Willebrand disease: plasma derived von Willebrand factor concentrates. Thromb Haemost 1997;78:566-570
23. Suiter P, Budde U, Metzner HJ, et al. Comparison von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF-collagen-binding-assays in VWF/FVIII-concentrates. J Thromb Haemost 2003:(suppl; abst):1667
24. Favaloro EJ. Collagen binding assay for von Willebrand factor (VWF: CBA): detection of von Willebrand Disease (VWD), and discrimination of VWD subtypes, depends on collagen source. Thromb Haemost 2000;83:127-135
25. Neugebauer BM, Goy C, Seitz R. A collagen binding assay, an additional method for von Willebrand factor activity in therapeutic concentrates. Thromb Haemost 2002;88:871-872
26. Hubbard AR, Dands D, Chang AC, et al. Standardisation of von Willebrand factor in therapeutic concentrates: calibration of the 1st International standard for von Willebrand factor concentrate (00/514). Thromb Haemost 2002;88: 380-386
27. Mannucci PM, Moia M, Rebulla P, et al. Correction of the bleeding time in treated patients with severe von Willebrand disease is not solely dependent on the normal multimeric structure of plasma von Willebrand factor. Am J Hematol 1987;25:55-65
28. Walter O, Budde U, Muysers C, et al. Determination of high-molecular-weight von Willebrand factor multimers and their impact on specific VWF-activities in VWF/FVIII concentrates. J Thromb Haemost 2003(suppl: abst):1673
29. Michiels JJ, Gadisseur A, Budde U, et al. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences. Semin Thromb Hemost 2005;31:577-601
30. Chang P, Aronson DL. Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities. Thromb Haemost 1997;78:930-933
31. European Directorate for the Quality of Medicines. Project on the von Willebrand factor monograph. Pharmeuropa 2005; 17.1:90-92
32. Morimoto Y, Yoshioka A, Sugimoto M, et al. Haemostatic management of intraoral bleeding in patients with von Willebrand disease. Oral Dis 2005;11:243-248
33. Favaloro EJ, Smith J, Petinos Pet al., on behalf of the RCPA Quality Assurance Program (QAP) in Hematology Scientific Hemostasis Advisory Panel.. Laboratory testing for von Willebrand's disease: an assessment of current diagnostic practice and efficacy by means of a multi-laboratory survey. Thromb Haemost 1999;82:1276-1282